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Background: Antiepileptic drugs (AEDs) are effective medications available for epilepsy. However, many patients
do not respond to this treatment and become resistant. Genetic polymorphisms may be involved in the variation
of AEDs response. Therefore, we conducted an updated systematic review and a meta-analysis to investigate the
contribution of the genetic profile on epilepsy drug resistance.
Methods: We proceeded to the selection of eligible studies related to the associations of polymorphisms with
resistance to AEDs therapy in epilepsy, published from January 1980 until November 2016, using Pubmed and
Cochrane Library databases. The association analysis was based on pooled odds ratios (ORs) and 95% confidence
intervals (CIs).
Results: From 640 articles, we retained 13 articles to evaluate the relationship between ATP-binding cassette
sub-family C member 1 (ABCB1) C3435T polymorphism and AEDs responsiveness in a total of 454 epileptic
AEDs-resistant cases and 282 AEDs-responsive cases. We found a significant association with an OR of 1.877,
95% CI 1.213–2.905. Subanalysis by genotype model showed a more significant association between the recessive
model of ABCB1 C3435T polymorphism (TT vs. CC) and the risk of AEDs resistance with an OR of 2.375, 95% CI 1.775–3.
178 than in the dominant one (CC vs. TT) with an OR of 1.686, 95% CI 0.877–3.242.
Conclusion: Our results indicate that ABCB1 C3435T polymorphism, especially TT genotype, plays an important role in
refractory epilepsy. As genetic screening of this genotype may be useful to predict AEDs response before starting the
treatment, further investigations should validate the association.
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Epilepsy is a chronic neurological worldwide disorder [1].
Most cases of epileptic patients respond to antiepileptic
drugs (AEDs). However, about one-third of epileptic pa-
tients develop recurrent seizures, despite the efficacy of
treatment at the optimal dose regimen. They are then,* Correspondence: chch.m@hotmail.fr
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international league against epilepsy (ILAE) redefined re-
fractory epilepsy in 2010 as the persistence of seizures
after two adequate trials of appropriate and tolerated
AEDs [3].
The exact mechanism of refractory epilepsy is not well
understood. Two main hypotheses are potentially in-
volved in the biological mechanism of AEDs resistance:
transporter and target hypotheses. The transporter hy-
pothesis supports the overexpression of drug efflux
transporters at the blood–brain barrier (BBB) reducing
AEDs access to the brain. The target hypothesis con-
tends that the changes in drug intracellular target sitesle is distributed under the terms of the Creative Commons Attribution 4.0
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Therefore, the two mechanisms prevent pharmacological
effects of antiepileptic at cerebral sites initiating seizures.
It seems that genetic polymorphisms of drug transporter
and target genes have a potential impact on the resistance
to treatment: they may be responsible for the mechanisms
of intractable epilepsy [5–7] by changing the function of
genes products [8–10] and leading to the AEDs failure
[4, 11–14]. Moreover, other authors have suggested that
they may involve the prognosis of newly treated epilepsy
[15]. Since drug-resistant epilepsy represents a major
problem in the control of seizures, the researchers focused
on the genetic profile to try to better understand the phar-
macoresistance for a more effective treatment.
Since drug resistance often occurs in patients with
multiple AEDs, the multidrug transporter hypothesis is
considered better than the target hypothesis to explain
the phenomenon of AEDs resistant epilepsy. However,
the two hypotheses may complement each other. Given
that drug transport mechanisms are the candidate mech-
anisms underlying AEDs resistance [16], many studies
took significantly into consideration the association be-
tween efflux transporters overexpression inducing recur-
rent seizures.
Bioavailability and response to medication in epilepsy
are mainly influenced by atp-binding cassette (ABC)
transporter superfamily. The atp-binding cassette sub-
family b member 1 (ABCB1) and the atp-binding cassette
sub-family c member 2 (ABCC2) also known as multidrug
resistance protein 1 (MDR1) and multidrug resistance
protein 2 (MDR2), located at the membrane of BBB endo-
thelial cells, are members of the ABC superfamily. They
are the most studied candidate genes in pharmacoresistant
epilepsy [5]. P-glycoprotein (P-gp) was the first human
ABC protein that has been discovered [17]. ABCB1 gene
encodes it and it affects a wide range of drugs distribution
in target compartments [18–20]. The C3435T polymorph-
ism is the most investigated polymorphism in the ABCB1
gene (single nucleotide polymorphism (SNP) in exon 26)
and it has received the most attention. It has been associ-
ated with the variations in the expression levels of P-gp
[21]. Previous studies focusing on the association between
ABCB1 C3435T polymorphism and drug-resistant epi-
lepsy showed discordant findings. Several studies have
supported the hypothesis of this association (alleles, geno-
types or haplotypes) to AEDs resistance [22–37]. However,
a number of studies conducted on epileptic patients from
different regions and ethnicities failed to confirm this re-
sult [38–42]. Subsequently, the opposed findings stimu-
lated some previous meta-analyses of which the majority
indicated that no association existed [43–49]. Besides,
G1249A polymorphism is one of the common polymor-
phisms in the ABCC2 gene (SNP in exon 10). The overex-
pression of the ABCC2 transporter protein reduces AEDslevels in brain tissues, which is a risk factor for pharma-
coresistant epilepsy. A genotypic association between this
polymorphism and responsiveness to AEDs has been sug-
gested in Asian populations [50, 51]. However, other
studies published contradictory results and they did not
find any association [42, 52–56]. Furthermore, only two
meta-analyses investigated its role in drug-resistant epi-
lepsy and found that ABCC2 G1249A polymorphism was
significantly associated with the decreased risk of AED re-
sistance [57, 58].
Among their pharmacological effects, some AEDs may
block voltage-dependent sodium channels [59, 60], which
stimulate the researchers to investigate the potential link
between drug-resistant epilepsy and polymorphisms in
channels genes like SCN1A gene. This gene is the most
studied drug target gene in epilepsy and it exhibits an in-
tronic polymorphism IVS5-91G > A, one of the most
common polymorphisms (SNP at intron splice donor site
of exon 5). It alters the proportion of human brain
NaV1.1-5N (exon 5N) and NaV1.1-5A (exon 5A) proteins,
but the functional impact of the splicing on NaV1.1 is un-
known. The correlation between SCN1A IVS5-91G > A
polymorphism and maximum doses of Oxcarbazepine
(OXC) may have a potential effect on resistant to epilepsy.
The same study found the same correlation for ABCC2
G1249A polymorphism [61]. An additional study reported
a genotypic association of SCN1A IVS5-91G > A poly-
morphism with the response to Carbamazepine (CBZ)/
OXC [51, 62], and another one showed its role on phar-
macoresponse to CBZ via an effect on GABAergic cortical
interneurons [63]. However, other studies [64–66] and
only one meta-analysis [67] were unable to replicate this
association.
Overall, even the most considered polymorphisms that
may explain mechanisms of pharmacoresistant epilepsy,
showed contradictory and inclusive results. Therefore,
we assembled pharmacogenetics (PGt) and pharmaco-
genomics (PGx) studies reporting associations between
AEDs resistant epilepsy and eventual polymorphisms.
Then, we performed an updated meta-analysis to clarify
their role in response to AEDs.
Methods
We defined search strategy, study selection criteria, data
elements and methods for study quality assessment.
Data sources and literature searches
We conducted a literature search using Pubmed and
Cochrane Library with English-language restriction from
January 1980 to November 2016. The key words used in
the search strategy were: “anti-epileptic drug(s)”, “antiepi-
leptic drug(s)”, “anti epileptic drug(s)” and “epilepsy” and
“efficacy”, “intractable”, “refractory”, “resistance”, “resist-
ant”, “response to treatment”, “pharmacoresistance”,
Chouchi et al. BMC Neurology  (2017) 17:32 Page 3 of 14“pharmacoresistant” and “genetic factor(s)”, “genotype(s)”,
“pharmacogenetic(s)”, “pharmacogenomic(s)”, “polymor-
phism(s)”, “variant(s)”, “variation(s)”, “SNP(s)”. We did not
search of additional publications. The reported results
followed the preferred reporting items for systematic re-
views and meta-analyses guidelines (PRISMA).Eligibility and inclusion criteria
For eligibility, we retained full-text publications showing a
relationship between genetic polymorphisms and respon-
siveness of AEDs in epilepsy (monotherapy or polytherapy).
The included studies met the following criteria: 1) Ori-
ginal research articles reported a genotypic evaluation of
polymorphisms and resistant epilepsy to antiepileptic
treatment. 2) Studies compared AEDs-resistant cases
with AEDs-responsive cases. 3) Studies showed sufficient
individual genotype frequencies for specific genotype
model. 4) At least three studies on the same polymorph-
ism were available in order to avoid the non-pertinence
of the results and the high risk of bias.Data extraction
Two independent authors performed the data eligibil-
ity, they extracted the following information from
each included study: first author, publication year,
ethnicity of the study population, the number of cases
and controls, genotype model for each polymorphism,
age, gender, aetiology, type of epilepsy, and AEDs
administered.Data synthesis and analysis
We calculated the association between polymorphisms and
AEDs resistant epilepsy using individual and overall odds
ratios (OR) with corresponding 95% confidence intervals
(CIs) by Forest Plot (Comprehensive Meta-Analysis Ver-
sion 3, USA). The P-value determined the significance of
the combined ORs. If the P-value (P) < 0.05, we considered
the pooled ORs statistically significant [68]. The Z-value
showed uniformisation of values and their position in the
full distribution of values in the program. The I2 statistic
test assessed statistical heterogeneity among included stud-
ies; if I2 < 50%, fixed-effects model pooled study data and if
I2 ≥ 50%, random-effects model pooled it [69]. Addition-
ally, we performed subgroup analysis using genotype
model to quantify the reported association between poly-
morphisms and AEDs resistant epilepsy in each reported
genotypic model. To identify publication bias between the
included studies, we applied Funnel plot and Egger’s re-
gression tests. The graph of Funnel plot reflected publica-
tion bias. Egger’s test assessed and confirmed funnel plot’s
results: P < 0.05 determined the existence of bias [70].Results
Evidence base
We identified a total of 640 potentially relevant articles.
We excluded a total of 591 publications from the further
analysis: abstract, articles showing absence of associations
between polymorphisms and AEDs resistant epilepsy
for insufficient data, case reports, duplicated articles,
letter to the editors, meta-analysis, not epileptic studies,
not human reports, researches about other treatments
than AEDs, review articles and studies not related to asso-
ciations between polymorphisms and AEDs resistant epi-
lepsy (Fig. 1).
Among the 49 reports that met eligibility requirements],
39 reviewed an association between polymorphisms and
epilepsy drug resistance [22–37, 50, 51, 62, 71–90]. We
identified the majority of polymorphisms in AEDs
transporter genes: ABCB1 and ABCC2. We also found
other polymorphisms in AEDs target genes: gamma-
aminobutyric acid-a receptor alpha1-subunit (GABRA1),
gamma-aminobutyric acid-a receptor alpha2-subunit
(GABRA2), gamma-aminobutyric acid-a receptor alpha3-
subunit (GABRA3), sodium channel nav1.1 (SCN1A), so-
dium channel nav1.2 (SCN2A), in other potential genes as
apolipoprotein e (ApoE), cytochrome p450 1a1 (CYP1A1),
cytochrome p450 family member 2c9 (CYP2C9),
gamma-aminobutyric acid transporter 3 (GAT3), gluta-
thione s-transferases mu 1 (GSTM1) and solute ligand
carrier family 6 member a4 (SLC6A4). We summarized
the characteristics of polymorphisms implicated in AEDs
resistance in different ethnic groups (Table 1). We ex-
cluded 10 full-text studies for insufficient data (Fig. 1).
Only 13 met the inclusion criteria and constituted the data
set for this analysis [22–29, 31, 33–36] (Table 2).
Data analysis
We carried out a meta-analysis to evaluate the relation-
ship between ABCB1 C3435T polymorphism and AEDs
resistance among AEDs-resistant patients vs. AEDs-
responsive patients. The included studies were heteroge-
neous for the study characteristics. The analysis of data
showed that 454 of 1653 AEDs-resistant patients
(27.465%) and 282 of 1732 AEDs-responsive patients
(16.282%) were included in the statistical analysis [22–
29, 31, 33–36]. The frequency of AEDs-resistant cases
was higher than AEDs-responsive patients. We divided
the age of cases and controls into three subgroups: >20
years, 20–40 years, and <40 years. We divided the gender
of cases and controls into two subgroups: males >50% and
males <50%. A total of eight included studies were
conducted in Asia [22, 23, 27–29, 34–36], three studies
in Europe [25, 26, 31], one study in Egypt [24] and
one another in Australia [33]. We classified the cases
by epilepsy syndrome (idiopathic, cryptogenic or
symptomatic epilepsy) [22, 23, 28, 31, 34, 36] or by
Fig. 1 PRISMA flow diagram: study methodology of excluded and included articles
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28, 29, 31, 33, 35, 36]. However, the classifications of
cases by epilepsy syndrome were not mentioned in seven
studies [24–27, 29, 33, 35] and the classifications of cases
by seizure types were not mentioned in three studies [26,
27, 34]. Two studies were stratified by epilepsy syndrome
[28, 31] and three studies were stratified by seizure types
[29, 33, 35]. Cases were treated with AEDs polytherapy
in seven studies [23, 26–29, 35, 36]. Only one study
reported association between ABCB1 C3435T poly-
morphism and cases with Phenytoin (PHT) therapy,
the administration of PHT as monotherapy or poly-
therapy was not mentioned [24]. However, AEDs
were not specified in five studies [22, 25, 27, 31, 33].
We summarized the characteristics of the available
included studies in Table 2.
Association of ABCB1 C3435T polymorphism with the
susceptibility to AEDs resistance
The heterogeneity among the included studies was high
(I2 = 82.961%, P < 10-3) and we used a random-effects model
[22–29, 31, 33–36]. The summary OR was 1.877, 95% CI
1.213–2.905, P = 0.005 showing that ABCB1 C3435T was
significantly associated with AEDs resistance (Fig. 2).
For the robustness of our findings, we used subanalysis
by dominant (CC vs. TT) and recessive (TT vs. CC)genotype models. The heterogeneity among the nine in-
cluded studies was high (I2 = 87.843%, P < 10-3) in the
dominant model [22–29, 31]. The summary OR was
1.686, 95% CI 0.877–3.242, P = 0.117 under a random-
effects model (Fig. 3). The analysis of the recessive model
revealed that the heterogeneity was absent (I2 = 0.000%,
P = 0.727) among the four included studies [33–36].
The summary OR was 2.375, 95% CI 1.775–3178, P < 10-3
under a fixed-effects model (Fig. 4). Therefore, the results
of our present meta-analysis indicates that the association
of ABCB1 C3435T polymorphism with the risk of AEDs
resistance, exists and it is more significant in ABCB1
3435TT genotype than in 3435CC genotype.
Analysis of publication bias
For the association between ABCB1 C3435T polymorph-
ism, ABCB1 3435CC, and 3435TT genotype models with
AEDs resistance, Funnel Plot showed asymmetrical ap-
pearances (Figs. 5, 6 and 7) and Egger’s regression test
showed that P = 0.413, P = 0.492, and P = 0.085, re-
spectively, were more than 0.05. The two tests demon-
strated a significant publication bias.
Discussion
Epilepsy is a serious health problem affecting about 65
million people worldwide and manifesting many
Table 1 Characteristics of reviewed studies reporting associations between polymorphisms and AEDs resistance epilepsy
Gene Polymorphism Genotype model Ethnicity Reference
ABCB1 c.1199G > A
(rs2229109)
GA vs. GG Mexican Escalante-Santiago et al. 2014 [71]
c.1236T > C
(rs1128503)
CC + CT vs. TT Iranian Maleki et al. 2010 [72]
c.2677G > T/A
(rs2032582)
AT + AG vs. GG + GT + TT Mexican Escalante-Santiago et al. 2014 [71]
TT vs. GG + GT European Sánchez et al. 2010 [31]
Malaysian Subenthiran et al. 2013 [37]
TT vs. GG Subenthiran et al. 2013 [73]
Japanese Seo et al. 2006 [36]
c.3435C > T
(rs1045642)
CC vs. TT Chinese Hung et al. 2005 [22]
Hung et al. 2007 [23]
Egyptian Ebid et al. 2007 [24]
European Sánchez et al. 2010 [31]
Siddiqui et al. 2003 [25]
Stasiołek et al. 2016 [26]
Indian Taur et al. 2014 [27]
Iranian Sayyah et al. 2011 [28]
Thai Keangpraphun et al. 2015 [29]
CC vs. CT + TT European Basic et al. 2008 [30]
Sánchez et al. 2010 [31]
CC + CT vs. TT Soranzo et al. 2004 [32]
CT vs. CC + TT Iranian Sayyah et al. 2011 [28]
TT vs. CC Australian Tan et al. 2004 [33]
Chinese Kwan et al. 2007 [34]
Indian Shaheen et al. 2014 [35]
Japanese Seo et al. 2006 [36]
TT vs. CT + CC Malaysian Subenthiran et al. 2013 [37]
ABCC2 c.-24C > T (rs717620) CT + TT vs. CC Chinese Qu et al. 2012 [74]
c.-1019A > G
(rs2804402)
AA vs. AG + GG Indian Grover et al. 2012 [75]
c.-1549G > A
(rs1885301)
GG vs. GA + AA
c.1249G > A
(rs2273697)
AA vs. GG Malaysian Sha’ari et al. 2014 [50]
Japanese
ChineseGA vs. GG
GA + AA vs. GG
GA vs. GG + AA Ma et al. 2014 [51]
c.3972C > T (rs3740066) CT vs. CC
CC + TT vs. CC
Malaysian Sha’ari et al. 2014 [50]
Chinese
CT + TT vs. CC Qu et al. 2012 [74]
TT vs. CC + CT Mexican Escalante-Santiago et al. 2014 [71]




e3/4 vs. e3/3 + e2/3 European Sporiš et al. 2005 [76]
c.388T > C
(rs429358)
e4 vs. e2 + e3 Chinese Gong et al. 2016 [77]
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Table 1 Characteristics of reviewed studies reporting associations between polymorphisms and AEDs resistance epilepsy (Continued)
CYP1A1 IVS1 + 606C > A
(rs2606345)
CC + CA vs. AA
CC vs. CA + AA
Indian Grover et al. 2010 [78]




European Seven et al. 2014 [79]
GABRA1 IVS11 + 15A > G
(rs2279020)
GG vs. AA + AG Indian Kumari et al. 2010 [80]
Kumari et al. 2011 [81]
c.74 + 448C > T (rs6883877) CC vs. TC + TT Thai Hung et al. 2013 [82]
GABRA2 g.46240004A > G
(rs511310)
GG vs. AA + AG
GABRA3 c.-27 + 37622A > G
(rs4828696)
TT vs. CC + CT
GAT3 c.1572C > T
(rs2272400)
CT + TT vs. CC Korean Kim et al. 2011 [83]
GSTM1 GSTM1*0 GSTM1- vs. GSTM1+ Chinese Liu et al. 2002 [84]
SCN1A c.3184A > G
(rs2298771)
AA vs. AG + GG Wang et al. 2014 [85]
AG + GG vs. AA Zhou et al. 2012 [86]
AG vs. AA + GG Egyptian Abo El Fotoh et al. 2016 [87]
IVS5-91G > A
(rs3812718)
AA vs. AG + GG Japanese Ma et al. 2014 [51]
Abe et al. 2008 [62]
SCN2A IVS7-32A > G
(rs2304016)
AA vs. AG + GG Chinese Kwan et al. 2008 [88]
SLC6A4 5-HTTLPR L/L vs. S/L + S/S European Hecimovic et al. 2010 [89]
STin2 VNTR 12/12 vs. 10/10 Argentinean Kauffman et al. 2009 [90]
12/12 vs. 10/12 + 10/10 European Hecimovic et al. 2010 [89]
Abbreviation: ABCB1 atp-binding cassette sub-family b member 1, ABCC2 atp-binding cassette subfamily c member 2, ApoE apolipoprotein e, CYP1A1 cytochrome
p450 1a1, CYP2C9 cytochrome p450 family member 2c9, GABRA1 gamma-aminobutyric acid-a receptor alpha1-subunit, GABRA2 gamma-aminobutyric acid-a recep-
tor alpha2-subunit, GABRA3 gamma-aminobutyric acid-a receptor alpha3-subunit, GAT3 gamma-aminobutyric acid transporter 3, GSTM1 glutathione s-transferases
mu 1, SCN1A sodium channel nav1.1, SCN2A sodium channel nav1.2, SLC6A4 solute ligand carrier family 6 member a4
Chouchi et al. BMC Neurology  (2017) 17:32 Page 6 of 14syndromes and types of seizures [60]. Since uncontrol-
lable seizures increase morbidity and mortality, drug-
resistant epilepsy is one of the major problems that phy-
sicians encounter. Recurrent seizures can devastate pa-
tients and their families. Therefore, drug-resistant
epilepsy still remains one of the main challenges for
epileptologists.
Since that genetic polymorphisms may play a role in re-
sponse to AEDs [10], we conducted an updated systematic
review in order to summarize the impact of polymor-
phisms in ABCB1, ABCC2, ApoE, CYP1A1, CYP2C9,
GABRA1, GABRA2, GABRA3, GAT3, GSTM1, SCN1A,
SCN2A, and SLC6A4 genes on AEDs resistant epilepsy.
Our meta-analysis concerned only the association between
ABCB1 C3435T polymorphism and drug-resistant epi-
lepsy, which revealed a significant risk to pharmacoresis-
tance (OR = 1.877, 95% CI 1.213–2.905, P = 0.005)
(Fig. 2). Some studies confirmed our results [22–37].
Nevertheless, many other reports failed to prove an asso-
ciation between ABCB1 C3435T polymorphism and re-
fractory epilepsy [38–42, 91–96].
The first publication showed that drug-resistant pa-
tients compared to drug-responsive patients, were morelikely to have the CC genotype than the TT genotype
(P = 0.006) [25]. Zimprich et al. confirmed the result
[97]. Moreover, many studies indicated that the CC
genotype were more prevalent in drug-resistant epilepsy
[12, 16–23]. However, three Asian studies [34–36] and
one Australian study [33] showed the opposite association
of TT genotype high frequency. In addition, our meta-
analysis showed that patients resistant to AEDs were more
likely to have ABCB1 3435TT genotype (OR = 2.375, 95%
CI 1.775–3.178, P < 10-3) than 3435CC genotype (OR =
1.686, 95% CI 0.877–3.242, P = 0.117) (Figs. 3 and 4).
Due to these controversial results, meta-analyses were
made in order to clarify the association between ABCB1
C3435T polymorphism and drug-resistant epilepsy. The
majority suggest that the ABCB1 C3435T polymorphism
may not be involved in the response to AEDs [58–62].
The study of Bournissen et al. showed no association of
ABCB1 C3435T polymorphism with risk of drug resist-
ance in overall and in the subgroup analysis by ethnicity
(Asian and Caucasian populations) (n = 3371 subjects)
[43]. The first study of Haerian et al. demonstrated the
lack of allelic association with the risk of drug resistance
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Fig. 2 Association between ABCB1 C3435T polymorphism and AEDs resistant epilepsy. Forest plot showed individual and overall ORs (black
squares) with corresponding 95% CIs (horizontal bars) by individual report. P-value showed statistical significance of ORs and Z-value showed
uniformisation of values and its position in the full distribution of values. Heterogeneity between the studies was mentioned
Chouchi et al. BMC Neurology  (2017) 17:32 Page 9 of 14subjects) [44] and the second study of Haerian et al.
showed no significant association of ABCB1 alleles, ge-
notypes, and haplotypes with recurrent seizures (n =
7067 patients) [45]. In the two studies, subanalysis of
studies by ethnicity (Asian and Caucasian populations)
yielded similar findings. Nurmohamed et al. failed to
find a statistical significance between genotypes of
ABCB1 C3435T polymorphism in cases and controls
(n = 3996 subjects) [46]. No allelic neither genotypic asso-
ciation of ABCB1 C3435T polymorphism with child-
hood risk of drug resistance was found in overall and
in the subgroup analysis by ethnicity (Asian and
Caucasian populations) (n = 1249 subjects) in the study of
Sun et al. [47]. Recently, two meta-analyses have indicated
that CC genotype was associated with recurrent seizures
in Caucasians. However, none of the genetic comparisonsFig. 3 Association between ABCB1 3435CC genotype and AEDs resistant ep
with corresponding 95% CIs (horizontal bars) by individual report. P-value s
uniformisation of values and its position in the full distribution of values. Hexhibited a significant association in Asians [63, 64]. In
our knowledge, no another meta-analysis showed the
same result as ours. Overall, meta-analyses stratified by
genotype genetic models in the overall studies, indicate
that the polymorphism may not play a major role in drug
resistance to AEDs [46] and similar results are found in
the subgroup analysis for the Asian and the Caucasian
populations [43–45, 47]. However, other meta-analyses
show a significant association in a specific ethnic sub-
group [63, 64]. These discrepant results are mainly due to
the small sample size, which is a common problem in as-
sociation studies leading to underpowered genotypic re-
sults. Worldwide collaboration between different centers
is then necessary to increase the sample size. In addition,
ethnicity is another factor that may affect the results. An
allele may become more common in ethnic subgroup butilepsy. Forest plot showed individual and overall ORs (black squares)
howed statistical significance of ORs and Z-value showed
eterogeneity between the studies was mentioned
Fig. 4 Association between ABCB1 3435TT genotype and AEDs resistant epilepsy. Forest plot showed individual and overall ORs (black squares)
with corresponding 95% CIs (horizontal bars) by individual report. P-value showed statistical significance of ORs and Z-value showed
uniformisation of values and its position in the full distribution of values. Heterogeneity between the studies was mentioned
Chouchi et al. BMC Neurology  (2017) 17:32 Page 10 of 14not in another, which may affect the response to AEDs
[45]. However, four meta-analyses show no evidence that
the ABCB1 C3435T polymorphism is associated with the
risk of resistance to AEDs in Asians and Caucasians
[43–45, 47]. Therefore, meta-analysis startified by eth-
nicity are needed to increase in order to confirm the
ethnic-dependence of AEDs resistant epilepsy.
AEDs transporters have contribute in pharmacoresis-
tant epilepsy. In fact, the most studied AEDs transporter
proteins like membrane proteins, are ABC transporter
superfamily members. They are ATP-dependent drug ef-
flux pumps for specific AED and are mainly encoded by
ABCB1 gene. ABCB1 protein or P-gp was transporte
AED in the BBB [72]. P-gp activity can be affected by
ABCB1 polymorphisms reducing plasmatic levels of
AEDs and minimizing antiepileptic treatment efficiency
in epileptic patients [98, 99]. If genetic background af-
fects the expression of P-gp, then penetration of AEDs in
the brain might depend on the patient’s genotype [16, 18].Fig. 5 Publication bias of the association between ABCB1 C3435T polymorpHomozygous TT genotype is associated with decreased
P-gp expression [4, 100].
Compared to literature search supporting conflicting re-
sults, our results show a higher contribution of ABCB1
3435TT genotype on response to AEDs. Our findings may
contribute to exhibit the implication of genetic markers in
refractory epilepsy before starting the treatment. In order
to have a better AEDs therapeutic response, the identifica-
tion of new potential genetic markers become necessary
against pharmcoresistance in epilepsy. This will lead to a
better understanding of drug resistance mechanisms in
epilepsy. Furthermore, it will be extremely important for
individual AEDs selection, early surgery feasibility and de-
velopment of new efficacious treatments.
Limitations
Our analysis is consistent to our strategy search, inclu-
sion criteria and statistical parameters. However, it may
be limited due to several factors: 1) Few number ofhism and AEDs resistant epilepsy
Fig. 6 Publication bias of the association between ABCB1 3435CC genotype model and AEDs resistant epilepsy
Chouchi et al. BMC Neurology  (2017) 17:32 Page 11 of 14included studies is insufficient to carry out a subgroup
analysis by ethnicity. In addition, the ethnicities in the
included studies are heterogeneous. PGt and PGx stud-
ies of AEDs resistance should be performed by ethnicity.
2) Publication bias and heterogeneity might have an im-
pact on the meta-analysis results. 3) Most of the included
studies match different types of epilepsy with different
AEDs. The affinity of each AED for ABC transporters is
variable. In fact, Valproic acid (VPA) is a widely used AED
and it is not transported by P-gp [101]. Thereby, the asso-
ciation between ABCB1 C3435T polymorphism and drug
resistance epilepsy could be affected. Correlation between
PGt and PGx results with specific AED should be required.
4) Different inclusion criteria are used to classify AEDs-
resistant patients in the included studies, subsequently, the
interpretation of the meta-analysis results become very
complex. In fact, AEDs-resistant patients were defined as
patients who had at least one seizure per month or 10 sei-
zures over the previous year, despite two or more AEDs atFig. 7 Publication bias of the association between ABCB1 3435TT genotypetherapeutic dosages and/or serum drug concentrations in
three studies [22, 28, 34]. In other reports, drug resistance
was defined as the occurrence of at least four seizures
over the year despite more than three appropriate
and tolerated AEDs for the epilepsy syndrome
[25, 31, 33]. In some studies, it was defined as the
failure of two appropriate and tolerated AEDs trials
[27, 29], with a poor clinical outcome and recurrent
seizures [35], or the occurrence of any types of seizures
for a minimum of one year at the same dose of AEDs [36],
or any seizures during the past three months [24] and
more than 10 seizures over the year [23].
Conclusions
Various studies have yielded contradictory findings regard-
ing the relationship between ABCB1 C3435T polymorph-
ism and AEDs resistance in epilepsy. In the current meta-
analysis, we demonstrate the existence of a statistical
significant association between ABCB1 3435TT genotypemodel and AEDs resistant epilepsy
Chouchi et al. BMC Neurology  (2017) 17:32 Page 12 of 14and refractory epilepsy. Therefore, the screening of
ABCB1 gene for this polymorphism in the future might be
useful to decide the best treatment option for each patient
and to predict the treatment outcome for new epileptic
patients. However, considering the few number of in-
cluded studies and the significant publication bias found
in this meta-analysis, further investigations should be
helpful to validate the use of this polymorphism in treat-
ment decisions.
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